SAREPTA THERAPEUTICS, INC. Depreciation
SAREPTA THERAPEUTICS, INC. (SRPT) reported Depreciation of $51.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. depreciation for the quarter ending 2014-03-31 was $400.00K, a 33.33% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. depreciation for the quarter ending 2013-03-31 was $300.00K.
- SAREPTA THERAPEUTICS, INC. depreciation for fiscal 2025 was $51.40M, a 20.37% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. depreciation for fiscal 2024 was $42.70M, a 0.47% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. depreciation for fiscal 2023 was $42.50M, a 6.25% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. depreciation for fiscal 2022 was $40.00M, a 9.29% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $51.40M 10-K · filed 2026-03-02 | ||
| 2024-12-31 | $42.70M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $42.50M 10-K · filed 2026-03-02 | ||
| 2022-12-31 | $40.00M 10-K · filed 2025-02-28 | ||
| 2021-12-31 | $36.60M 10-K · filed 2024-02-28 | ||
| 2020-12-31 | $25.20M 10-K · filed 2023-02-28 | ||
| 2019-12-31 | $22.80M 10-K · filed 2022-03-01 | ||
| 2018-12-31 | $10.20M 10-K · filed 2021-03-01 | ||
| 2017-12-31 | $6.40M 10-K · filed 2020-02-26 | ||
| 2016-12-31 | $5.00M 10-K · filed 2019-02-28 | ||
| 2015-12-31 | $4.70M 10-K · filed 2018-03-01 | ||
| 2014-12-31 | $3.20M 10-K · filed 2017-02-28 | ||
| 2014-03-31 | $400.00K 10-Q · filed 2014-05-08 | ||
| 2013-12-31 | $800.00K 10-K · filed 2016-02-25 | ||
| 2013-03-31 | $300.00K 10-Q · filed 2014-05-08 | ||
| 2012-12-31 | $1.00M 10-K · filed 2015-02-26 | $975.00K 10-K · filed 2013-03-15 | |
| 2011-12-31 | $800.00K 10-K · filed 2014-03-03 | $838.00K 10-K · filed 2013-03-15 | |
| 2010-12-31 | $1.22M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |